Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CACNA1G antisense RNA 1 (CACNA1G-AS1)
- Target
- CACNA1G-AS1
- Molecular classification
- Long non-coding RNA (lncRNA), Other (regulatory RNA, not encoding protein)
01
Overview
CACNA1G antisense RNA 1 (CACNA1G-AS1) is a long non-coding RNA transcribed from the antisense strand of the CACNA1G locus. It acts as a regulatory RNA, modulating the expression of CACNA1G (a calcium channel protein) and other genes involved in cell proliferation, migration, invasion, and apoptosis. Elevated levels of CACNA1G-AS1 have been observed in diseases such as keloid disorder and several cancers, where it commonly promotes pathological cell behaviors by antagonizing specific microRNAs (notably miR-205 and miR-3160-5p). These features make CACNA1G-AS1 a promising biomarker and therapeutic target for various disorders characterized by aberrant cell growth and survival.
- Other names
- CAS1CACNA1G antisense RNA 1 (non-protein coding)CACNA1G-AS1
02
Mechanism of action
Targeted knockdown of CACNA1G-AS1 (e.g., with siRNAs) leads to decreased proliferation and invasion, and increased apoptosis in disease-relevant cells. CACNA1G-AS1 acts as a competing endogenous RNA (ceRNA), sponging specific microRNAs (miR-205 in keloids, miR-3160-5p in lymphoma), thereby derepressing target mRNAs involved in cell survival, migration, or extracellular matrix production.
03
Biological functions
Regulation of cell proliferationRegulation of cell migration and invasionRegulation of apoptosisRegulation of collagen (especially type I) expressionControl of calcium channel protein expression (specifically CACNA1G)Interaction with microRNAs (miR-205 in keloids, miR-3160-5p in DLBCL)
04
Disease associations
Cancer (e.g., diffuse large B-cell lymphoma, hepatocellular carcinoma, lung non-small cell carcinoma)Benign hyperproliferative disease (keloid disorder)Other (possible roles in retinitis pigmentosa and other pathological states per genome database associations)
05
Safety considerations
The therapeutic challenge is achieving tissue-specific silencing of lncRNA without off-target effects on normal cell regulation, as lncRNAs may have pleiotropic roles.There is no safety signal reported for direct targeting of CACNA1G-AS1 in clinical settings, as all interventions remain preclinical (e.g., siRNA-mediated knockdown in cell or animal models). Potential risks are theoretical, including dysregulation of normal cell apoptosis or tissue remodeling.
06
Biomarkers
Active or proliferative keloid fibroblastsDiffuse large B-cell lymphoma, especially advanced-stage diseaseOther roles as an expression biomarker in certain cancers remain to be validated
Beyond the preview
Go deeper on CACNA1G antisense RNA 1 (CACNA1G-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CACNA1G antisense RNA 1 (CACNA1G-AS1).